Drugs Made In America Acquisition (DMAA) Total Liabilities (2024 - 2025)
Drugs Made In America Acquisition (DMAA) reported Total Liabilities of $7.3 million for Q4 2025, up 814.47% on a YoY basis from $795669.0 in Q4 2024, and down 1.09% quarter-over-quarter from $7.4 million in Q3 2025.
Drugs Made In America Acquisition (DMAA) Total Liabilities (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition has reported Total Liabilities for 2 years, with the latest figure at $7.3 million in Q4 2025.
- For the quarter ending Q4 2025, Total Liabilities rose 814.47% year-over-year to $7.3 million; the trailing twelve-month figure through Dec 2025 stood at $7.3 million (up 814.47% YoY), and the FY2025 full-year result was $7.3 million, up 814.47% from the prior year.
- Total Liabilities for Q4 2025 stood at $7.3 million, down from $7.4 million in the prior quarter.
- The five-year high for Total Liabilities was $7.4 million in Q3 2025, with the low at $795669.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - | 18.40 Mn |
| 2 | Berto Acquisition | 312.46 Mn | 312.46 Mn | - | 12.59 Mn |
| 3 | Centurion Acquisition | 311.65 Mn | 311.65 Mn | - | 13.84 Mn |
| 4 | GP-Act III Acquisition | 311.36 Mn | 311.36 Mn | - | 14.67 Mn |
| 5 | Churchill Capital Corp IX | 310.79 Mn | 310.79 Mn | - | 11.51 Mn |
| 6 | WEN Acquisition | 309.15 Mn | 309.15 Mn | - | 14.42 Mn |
| 7 | Bold Eagle Acquisition | 275.54 Mn | 275.54 Mn | - | 9.81 Mn |
| 8 | Soulpower Acquisition | 264.91 Mn | 264.91 Mn | - | 13.99 Mn |
| 9 | BTC Development | 262.16 Mn | 262.16 Mn | - | 10.91 Mn |
| 10 | Drugs Made In America Acquisition | 223.11 Mn | 223.11 Mn | - | 7.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.28 Mn |
| Sep 30, 2025 | 7.36 Mn |
| Jun 30, 2025 | 7.20 Mn |
| Mar 31, 2025 | 7.25 Mn |
| Dec 31, 2024 | 795,669.00 |